Alkermes sinks after reporting Aristada sales miss

Alkermes shares fell $4.44 (13%) to $30.31 Thursday after the company reported quarterly sales of schizophrenia therapy Aristada that fell short of both its own guidance and analysts' expectations. The company attributed

Read the full 325 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE